Table 4.
Multivariate Cox regression analyses for predicting OS, DSS and DFS of patients with BC in the training cohort
| Characteristics | OS | DSS | DFS | |||
|---|---|---|---|---|---|---|
| HR (95% CI) | P value | HR (95% CI) | P value | HR (95% CI) | P value | |
| T stage | ||||||
| Ta | Reference | Reference | Reference | |||
| T1 | 2.148 (0.662-6.967) | 0.203 | 1.275 (0.345-4.705) | 0.716 | 0.684 (0.354-1.320) | 0.257 |
| T2 | 0.734 (0.080-6.747) | 0.785 | 0.828 (0.088-7.820) | 0.869 | 0.853 (0.335-2.174) | 0.740 |
| T3 and T4 | 2.790 (0.606-12.856) | 0.188 | 1.910 (0.331-11.015) | 0.469 | 0.253 (0.057-1.137) | 0.073 |
| Tumor grade (high/low) | 5.170 (1.071-24.944) | 0.041* | 4.305 (0.853-21.729) | 0.077 | 5.428 (2.519-11.700) | <0.001* |
| Tumor multifocality (yes/no) | 1.891 (0.753-4.753) | 0.175 | 2.569 (0.834-7.917) | 0.100 | 1.851 (1.062-3.224) | 0.030* |
| AFR (≤12.21/>12.21) | 2.601 (1.057-6.395) | 0.037* | 2.189 (0.727-6.590) | 0.164 | 1.971 (1.049-3.703) | 0.035* |
Note: * P value<0.05.
Abbreviations: OS: overall survival; DSS: disease-specific survival; DFS: disease-free survival; BC: bladder cancer; HR: hazard ratio; CI: confidence interval; AFR: albumin-to-fibrinogen ratio.